317 related articles for article (PubMed ID: 15824861)
21. Reduced bone mineral density and hyaloid vasculature remnants in a consanguineous recessive FEVR family with a mutation in LRP5.
Downey LM; Bottomley HM; Sheridan E; Ahmed M; Gilmour DF; Inglehearn CF; Reddy A; Agrawal A; Bradbury J; Toomes C
Br J Ophthalmol; 2006 Sep; 90(9):1163-7. PubMed ID: 16929062
[TBL] [Abstract][Full Text] [Related]
22. Mutations in Known Monogenic High Bone Mass Loci Only Explain a Small Proportion of High Bone Mass Cases.
Gregson CL; Wheeler L; Hardcastle SA; Appleton LH; Addison KA; Brugmans M; Clark GR; Ward KA; Paggiosi M; Stone M; Thomas J; Agarwal R; Poole KE; McCloskey E; Fraser WD; Williams E; Bullock AN; Davey Smith G; Brown MA; Tobias JH; Duncan EL
J Bone Miner Res; 2016 Mar; 31(3):640-9. PubMed ID: 26348019
[TBL] [Abstract][Full Text] [Related]
23. Pregnancy-associated osteoporosis with a heterozygous deactivating LDL receptor-related protein 5 (LRP5) mutation and a homozygous methylenetetrahydrofolate reductase (MTHFR) polymorphism.
Cook FJ; Mumm S; Whyte MP; Wenkert D
J Bone Miner Res; 2014 Apr; 29(4):922-8. PubMed ID: 24014470
[TBL] [Abstract][Full Text] [Related]
24. Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5.
Simpson CA; Foer D; Lee GS; Bihuniak J; Sun B; Sullivan R; Belsky J; Insogna KL
Osteoporos Int; 2014 Oct; 25(10):2383-8. PubMed ID: 24927689
[TBL] [Abstract][Full Text] [Related]
25. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity.
Korvala J; Jüppner H; Mäkitie O; Sochett E; Schnabel D; Mora S; Bartels CF; Warman ML; Deraska D; Cole WG; Hartikka H; Ala-Kokko L; Männikkö M
BMC Med Genet; 2012 Apr; 13():26. PubMed ID: 22487062
[TBL] [Abstract][Full Text] [Related]
26. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.
Sawakami K; Robling AG; Ai M; Pitner ND; Liu D; Warden SJ; Li J; Maye P; Rowe DW; Duncan RL; Warman ML; Turner CH
J Biol Chem; 2006 Aug; 281(33):23698-711. PubMed ID: 16790443
[TBL] [Abstract][Full Text] [Related]
27. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.
Little RD; Carulli JP; Del Mastro RG; Dupuis J; Osborne M; Folz C; Manning SP; Swain PM; Zhao SC; Eustace B; Lappe MM; Spitzer L; Zweier S; Braunschweiger K; Benchekroun Y; Hu X; Adair R; Chee L; FitzGerald MG; Tulig C; Caruso A; Tzellas N; Bawa A; Franklin B; McGuire S; Nogues X; Gong G; Allen KM; Anisowicz A; Morales AJ; Lomedico PT; Recker SM; Van Eerdewegh P; Recker RR; Johnson ML
Am J Hum Genet; 2002 Jan; 70(1):11-9. PubMed ID: 11741193
[TBL] [Abstract][Full Text] [Related]
28. High bone mass in mice expressing a mutant LRP5 gene.
Babij P; Zhao W; Small C; Kharode Y; Yaworsky PJ; Bouxsein ML; Reddy PS; Bodine PV; Robinson JA; Bhat B; Marzolf J; Moran RA; Bex F
J Bone Miner Res; 2003 Jun; 18(6):960-74. PubMed ID: 12817748
[TBL] [Abstract][Full Text] [Related]
29. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.
Jacobsen CM; Barber LA; Ayturk UM; Roberts HJ; Deal LE; Schwartz MA; Weis M; Eyre D; Zurakowski D; Robling AG; Warman ML
J Bone Miner Res; 2014 Oct; 29(10):2297-306. PubMed ID: 24677211
[TBL] [Abstract][Full Text] [Related]
30. The high bone mass family--the role of Wnt/Lrp5 signaling in the regulation of bone mass.
Johnson ML
J Musculoskelet Neuronal Interact; 2004 Jun; 4(2):135-8. PubMed ID: 15615112
[TBL] [Abstract][Full Text] [Related]
31. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations.
Balemans W; Piters E; Cleiren E; Ai M; Van Wesenbeeck L; Warman ML; Van Hul W
Calcif Tissue Int; 2008 Jun; 82(6):445-53. PubMed ID: 18521528
[TBL] [Abstract][Full Text] [Related]
32. Low-density lipoprotein receptor-related protein 5 (LRP5) variation in fracture prone children.
Saarinen A; Mäyränpää MK; Lehesjoki AE; Mäkitie O
Bone; 2010 Apr; 46(4):940-5. PubMed ID: 20045498
[TBL] [Abstract][Full Text] [Related]
33. Various types of LRP5 mutations in four patients with osteoporosis-pseudoglioma syndrome: identification of a 7.2-kb microdeletion using oligonucleotide tiling microarray.
Narumi S; Numakura C; Shiihara T; Seiwa C; Nozaki Y; Yamagata T; Momoi MY; Watanabe Y; Yoshino M; Matsuishi T; Nishi E; Kawame H; Akahane T; Nishimura G; Emi M; Hasegawa T
Am J Med Genet A; 2010 Jan; 152A(1):133-40. PubMed ID: 20034086
[TBL] [Abstract][Full Text] [Related]
34. Bone biomechanical properties in LRP5 mutant mice.
Akhter MP; Wells DJ; Short SJ; Cullen DM; Johnson ML; Haynatzki GR; Babij P; Allen KM; Yaworsky PJ; Bex F; Recker RR
Bone; 2004 Jul; 35(1):162-9. PubMed ID: 15207752
[TBL] [Abstract][Full Text] [Related]
35. Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG).
Laine CM; Chung BD; Susic M; Prescott T; Semler O; Fiskerstrand T; D'Eufemia P; Castori M; Pekkinen M; Sochett E; Cole WG; Netzer C; Mäkitie O
Eur J Hum Genet; 2011 Aug; 19(8):875-81. PubMed ID: 21407258
[TBL] [Abstract][Full Text] [Related]
36. Osteoporosis-pseudoglioma syndrome: three novel mutations in the LRP5 gene and response to bisphosphonate treatment.
Tüysüz B; Bursalı A; Alp Z; Suyugül N; Laine CM; Mäkitie O
Horm Res Paediatr; 2012; 77(2):115-20. PubMed ID: 22456437
[TBL] [Abstract][Full Text] [Related]
37. Mutations in WNT1 cause different forms of bone fragility.
Keupp K; Beleggia F; Kayserili H; Barnes AM; Steiner M; Semler O; Fischer B; Yigit G; Janda CY; Becker J; Breer S; Altunoglu U; Grünhagen J; Krawitz P; Hecht J; Schinke T; Makareeva E; Lausch E; Cankaya T; Caparrós-Martín JA; Lapunzina P; Temtamy S; Aglan M; Zabel B; Eysel P; Koerber F; Leikin S; Garcia KC; Netzer C; Schönau E; Ruiz-Perez VL; Mundlos S; Amling M; Kornak U; Marini J; Wollnik B
Am J Hum Genet; 2013 Apr; 92(4):565-74. PubMed ID: 23499309
[TBL] [Abstract][Full Text] [Related]
38. A cell-based Dkk1 binding assay reveals roles for extracellular domains of LRP5 in Dkk1 interaction and highlights differences between wild-type and the high bone mass mutant LRP5(G171V).
Murrills RJ; Matteo JJ; Bhat BM; Coleburn VE; Allen KM; Chen W; Damagnez V; Bhat RA; Bex FJ; Bodine PV
J Cell Biochem; 2009 Dec; 108(5):1066-75. PubMed ID: 19746449
[TBL] [Abstract][Full Text] [Related]
39. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST.
Semenov MV; He X
J Biol Chem; 2006 Dec; 281(50):38276-84. PubMed ID: 17052975
[TBL] [Abstract][Full Text] [Related]
40. Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells.
Qiu W; Andersen TE; Bollerslev J; Mandrup S; Abdallah BM; Kassem M
J Bone Miner Res; 2007 Nov; 22(11):1720-31. PubMed ID: 17680723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
